Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
Day One Biopharmaceuticals was a Nasdaq-listed biopharmaceutical company focused on targeted therapies for people of all ages with life-threatening diseases. News about DAWN centered on oncology product and pipeline developments, including OJEMDA (tovorafenib), an FDA-approved medicine marketed in the U.S. for pediatric low-grade glioma, and clinical-stage assets in rare cancers.
Coverage also includes the completed acquisition by Servier, related shareholder-rights and governance notices, capital-structure updates, operating and financial results, and clinical or regulatory disclosures tied to OJEMDA and other oncology programs.
Servier completed its acquisition of Day One Biopharmaceuticals (Nasdaq: DAWN) on April 23, 2026, for $21.50 per share, implying a total equity value of approximately $2.5 billion.
The deal adds OJEMDATM (tovorafenib), an FDA‑approved therapy for pediatric low‑grade glioma, and a clinical‑stage oncology pipeline including Emi‑Le and DAY301. Ipsen holds rights outside the U.S.
Servier agreed to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, implying a total equity value of ~$2.5 billion. The transaction, expected to close in Q2 2026, expands Servier's rare oncology pipeline, notably a lead program in pediatric low-grade glioma.
The offer price represents ~68% premium to Day One's March 5, 2026 close and ~86% premium to one-month VWAP as of March 5, 2026. Closing is subject to a majority tender and U.S. antitrust clearance.
Day One (Nasdaq: DAWN) reported Q4 and full-year 2025 results and reaffirmed 2026 guidance. OJEMDA net product revenue was $52.8M in Q4 and $155.4M for 2025, a 172% YoY increase; total prescriptions rose 181% to 4,635. The company reaffirmed 2026 U.S. OJEMDA revenue guidance of $225M–$250M. Day One acquired Mersana in January 2026; Emi-Le Phase 1 data expected mid-2026. FIREFLY-2 enrollment is on track to complete in H1 2026. Cash, cash equivalents and short-term investments were $441.1M as of December 31, 2025; FY net loss was $107.3M.
Day One Biopharmaceuticals (Nasdaq: DAWN) will report fourth-quarter and full-year 2025 financial results on Tuesday, February 24, 2026 at 4:30 p.m. ET. The company will host a live conference call and webcast to discuss results and corporate progress.
Live audio will be accessible via the Events section of Day One's Media & Investors page, and an archived replay will be available for 30 days following the event.
Day One (Nasdaq: DAWN) reported preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, with Q4 2025 revenue of $52.8 million (~37% QoQ growth) and 1,394 prescriptions in Q4. The company provided 2026 OJEMDA U.S. net product revenue guidance of $225–$250 million (midpoint ≈ 53% YoY growth). As of Dec 31, 2025, prior to the Mersana acquisition, Day One held approximately $441.1 million of cash, cash equivalents, and short-term investments (unaudited). Key near-term milestones include completing Phase 3 FIREFLY-2 enrollment in 1H 2026 (mid-2027 readout) and planned Phase 1 data for Emi-Le by mid-2026 and DAY301 in 2H 2026.
Day One (Nasdaq: DAWN) completed its acquisition of Mersana Therapeutics on January 6, 2026, acquiring all outstanding shares for $25 per share in cash plus one non-tradable contingent value right (CVR) per share for potential milestone payments up to $30.25 per CVR, for total consideration of up to $55.25 per share.
The tender offer expired Jan. 5, 2026 with 3,029,135 shares validly tendered (representing 60.57% of Mersana outstanding). Following a statutory merger under Delaware law, Mersana became a direct wholly owned subsidiary of Day One and its Nasdaq common stock will be delisted prior to market open on Jan. 6, 2026. Day One adds clinical-stage ADC emiltatug ledadotin (Emi-Le), targeting B7-H4 and adenoid cystic carcinoma (ACC), to its pipeline.
Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET. A live audio webcast will be available via the company’s News & Events web page and an archived replay will be accessible for 30 days after the live presentation.
Day One (Nasdaq: DAWN) reported three-year follow-up data from the Phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) in relapsed/refractory pediatric low-grade glioma (data cutoff June 6, 2025; median study duration 40.6 months).
Key results in 76 evaluable patients: overall response rate 53%, median duration of response 19.4 months, median PFS 16.6 months, and median time-to-next-treatment 42.6 months. Of 39 patients entering treatment-free observation, 77% remained off therapy ≥12 months. No new safety signals; Grade ≥3 events (≥5%) listed.
Day One (Nasdaq: DAWN) announced management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. EST.
A live webcast will be available via the Events section of the Day One Media & Investors page, and an archived replay will be available for 30 days after the live event.
Day One (NASDAQ: DAWN) signed a definitive merger agreement to acquire Mersana Therapeutics for $25 per share cash plus one non-tradable CVR, with total consideration up to $55.25 per share and an approximate equity value at closing of $129 million (total deal value up to ~$285 million). The acquisition adds emiltatug ledadotin (Emi-Le), an antibody‑drug conjugate targeting B7-H4, which showed early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type‑1 (ACC‑1).
Milestone CVR payments total up to $30.25 per share tied to clinical, regulatory, and sales milestones. Day One expects to fund the transaction with existing cash and aims to close by end of January 2026, subject to regulatory approvals and customary conditions.